Rankings
▼
Calendar
FHTX Q4 2021 Earnings — Foghorn Therapeutics Inc. Revenue & Financial Results | Market Cap Arena
FHTX
Foghorn Therapeutics Inc.
$330M
Q4 2021 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$713,000
+184.1% YoY
Gross Profit
-$22M
-3050.5% margin
Operating Income
-$28M
-3938.6% margin
Net Income
-$29M
-4087.4% margin
EPS (Diluted)
$4.62
QoQ Revenue Growth
+1639.0%
Cash Flow
Operating Cash Flow
$12M
Free Cash Flow
$12M
Stock-Based Comp.
$2M
Balance Sheet
Total Assets
$520M
Total Liabilities
$423M
Stockholders' Equity
$97M
Cash & Equivalents
$101M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$713,000
$251,000
+184.1%
Gross Profit
-$22M
-$312,000
-6871.2%
Operating Income
-$28M
-$21M
-35.1%
Net Income
-$29M
-$21M
-40.4%
← FY 2021
All Quarters
Q1 2022 →